Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors
ChemMedChem · 2026
DOI: 10.1002/cmdc.70428 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2026. Verfasst von Francesco Saccoliti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Health and Health Professions, Link Campus University, Rome, Italy. Hauptthemen laut MEDLINE: HIV Integrase Inhibitors, HIV Integrase, Drug Discovery, HIV-1. Die Arbeit nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Sapienza Università di Roma, Ministry for Universities and Research, Italy.
Abstract (Originalsprache)
Given its pivotal role in the viral life cycle, blocking integrase (IN) through IN strand transfer inhibitors (INSTIs) represented a breakthrough in the treatment of HIV infection, establishing these antiretroviral regimens as first‐line options against AIDS. However, the onset of drug‐resistant strains has challenged the efficacy of INSTIs, demanding new efforts in the search for therapeutic tools that work through alternative modes of action. In this context, the discovery of allosteric IN inhibitors (ALLINIs) has highlighted new opportunities to target IN beyond its active site, enhancing antiviral efficacy and the genetic barrier to resistance. Extensive drug discovery campaigns have resulted in the development of effective ALLINIs with both in vitro and in vivo efficacy, two of which are advancing in clinical trials as next‐generation therapeutic tools. Nevertheless, advancements in structural biology have critically aided in elucidating the underlying effects of ALLINIs, highlighting a complex, multimodal mode of action that ultimately yields defects in virion maturation. This review focuses on ALLINIs, providing a comprehensive overview of major drug discovery efforts devoted to this field, with an emphasis on the medicinal chemistry and structural biology findings that have revealed unprecedented opportunities for developing innovative and effective anti‐HIV drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Science, Health and Health Professions, Link Campus University, Rome, Italy.
- Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, Rome, Italy.
- Dottorato di Interesse Nazionale in One Health Approaches to Infectious Diseases and Life Science Research, Dipartimento di Sanità Pubblica Medicina Sperimentale e Forense, Università degli Studi di Pavia, Pavia, Italy.
- Department of Science, Roma Tre University, Rome, Italy.
ORCID-Profile: Francesco Saccoliti, Elisa Patacchini, Emanuele Cara, Laura Zarbo, Antonella Messore, Aurora Albano, Giuseppe Ruggieri, Valentina Noemi Madia, Luigi Scipione, Roberto Di Santo
Förderung
- Ministero dell'Università e della Ricerca
- Sapienza Università di Roma
- Ministry for Universities and Research, Italy
- Sapienza University of Rome
Zitieren
APA
Saccoliti, F., Patacchini, E., Cara, E., Zarbo, L., Messore, A., Albano, A., Ruggieri, G., Madia, V. N., Scipione, L., Costi, R., & Di Santo, R. (2026). Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.70428
Vancouver
Saccoliti F, Patacchini E, Cara E, Zarbo L, Messore A, Albano A, et al. Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors. ChemMedChem. 2026. doi:10.1002/cmdc.70428
BibTeX
@article{Saccoliti2026,
author = {Saccoliti, Francesco and Patacchini, Elisa and Cara, Emanuele and Zarbo, Laura and Messore, Antonella and Albano, Aurora and Ruggieri, Giuseppe and Madia, Valentina Noemi and Scipione, Luigi and Costi, Roberta and Di Santo, Roberto},
title = {Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70428}
}
EUVIMED